atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL-007 for Cognitive Impairment...

Mon, Dec 19

Perspectives

Today we announced the initiation of a Phase 2b proof-of-concept clinical trial of RL-007 for Cognitive Impairment Associated with #Schizophrenia, for which there are currently no @US_FDA-approved treatments. cc @flobrand @C_Angermayer sub #mentalhealth https://t.co/6Ku5xVEWpK

The phase 2b proof-of-concept trial will evaluate the novel compound, RL-007, for pro-cognitive effects in patients with Cognitive Impairment Associated with Schizophrenia (CIAS). The trial was...

Discover